Photocure $PHO.OL renewed breakout watch ahead of Q2 report
Investors are eagerly awaiting Photocures 
PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management.
Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK:
https://www.edisongroup.com/publication/a-licensing-deal-for-cevira/24556/
PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management.
Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK:
https://www.edisongroup.com/publication/a-licensing-deal-for-cevira/24556/
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.